Analyses of CT scans over the course of one year can help to predict long-term outcomes among people with…
Marisa Horak, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Horak, MS
Health Canada has approved Boehringer Ingelheim‘s oral therapy Jascayd (nerandomilast) as a treatment for adults with idiopathic…
Admilparant, an experimental oral therapy being developed by Bristol Myers Squibb, slowed lung function declines among people with…
Computer-based analyses of CT scans can help to predict future disease progression and track response to treatment among people with…
September is Pulmonary Fibrosis Awareness Month, and advocates around the globe are joining together to shine a light on what…
The inhaled therapy MNKD-201 was tolerated well in people with idiopathic pulmonary fibrosis (IPF) in a Phase 1 clinical…
An international clinical trial testing LTI-03, Rein Therapeutics’ inhaled treatment candidate for idiopathic pulmonary fibrosis (IPF), is now…
The oral therapy Jascayd (nerandomilast) has been approved in the European Union for adults with idiopathic pulmonary fibrosis…
The Pulmonary Fibrosis Foundation (PFF), an advocacy group dedicated to advancing care for people with pulmonary fibrosis, has…
Two Phase 3 clinical trials testing Tyvaso (treprostinil) in people with idiopathic pulmonary fibrosis (IPF) both met their…